Page 14 - Multiple Sclerosis Ms News Today

The wearable EksoNR robotic exoskeleton is the first FDA-cleared exoskeleton for use in the rehabilitation of patients with multiple sclerosis.

In a new study of more than 600 patients with multiple sclerosis, about 1 in 25 faced a potentially severe drug-drug interaction, with more having at least one potentially risky interaction.

The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.

The investigational evobrutinib, an Brutons tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.

General neurologists fall short in their knowledge of key multiple sclerosis diagnostic criteria standards compared with MS experts, new findings show, which may be detrimental to patient management.

Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.

Over 25 years of clinical research, phase 3 trials of approved disease-modifying therapies for multiple sclerosis were overwhelmingly made up of White participants, new research shows.

A B-cell count of at least 40/µL is necessary to mount an adequate antibody response to COVID-19 boosters in patients with multiple sclerosis, new research shows.

Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.

Data on repair or progression in normal-appearing brain tissue on conventional MRI.